A new frontier in personalized cancer therapy: Mapping molecular changes

Future Oncology

Volumn 7, Issue 7, 2011, Pages 873-894

  Kasaian, Katayoon ^a   Jones, Steven Jm ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

biomarker; next generation sequencing; personalized cancer therapy; pharmacogenomics; SNP genotyping; targeted medicine

Indexed keywords

ALPHA INTERFERON; ARSENIC TRIOXIDE; B RAF KINASE; BCR ABL PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CETUXIMAB; CYTARABINE; DACARBAZINE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROURACIL; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IRINOTECAN; JANUS KINASE 1; JANUS KINASE 2; LAPATINIB; MERCAPTOPURINE; NILOTINIB; OLAPARIB; PANITUMUMAB; PROMYELOCYTIC LEUKEMIA PROTEIN; PROSTATE SPECIFIC ANTIGEN; RUXOLITINIB; TRASTUZUMAB; VEMURAFENIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALTERNATIVE RNA SPLICING; BREAST CANCER; CANCER GENETICS; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CANCER; CYTOGENETICS; DNA SEQUENCE; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC LINKAGE; GENETIC VARIABILITY; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HIGH THROUGHPUT SEQUENCING; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MICROARRAY ANALYSIS; MYELOID METAPLASIA; ONCOGENE H RAS; ONCOGENE K RAS; OVARY CANCER; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PHILADELPHIA 1 CHROMOSOME; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEOMICS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; THROMBOCYTHEMIA; TRANSCRIPTOMICS; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

ANIMALS; EPIGENOMICS; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PHARMACOGENETICS; PROTEOMICS;

EID: 79960122936     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.63     Document Type: Review

References (336)

1. Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a systems biology approach. J. Clin. Oncol. 28(16), 2777-2783 (2010)
2. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat. Rev. Clin. Oncol. 8(3), 184-187 (2011)
3. Potti A, Schilsky RL, Nevins JR. Refocusing the war on cancer: the critical role of personalized treatment. Sci. Transl. Med. 2(28), 28CM13 (2010)
4. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early breast cancer trialists? collaborative group. Lancet 352(9132), 930-942 (1998)
5. van?t Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452(7187), 564-570 (2008)
6. Joyce AR, Palsson BO. The model organism as a system: integrating ?omics? data sets. Nat. Rev. Mol. Cell. Biol. 7(3), 198-210 (2006)
7. Khalil IG, Hill C. Systems biology for cancer. Curr. Opin. Oncol. 17(1), 44-48 (2005) (Pubitemid 40179911)
8. Boveri T. Zur Frage der Entstehung Maligner Tumoren. Science 40(1041), 857-859 (1914)
9. von Hansemann D. Ueber asymmetrische Zellteilung in epithel Krebsen und deren biologische Bedeutung. Virchow?s Arch. Path. Anat. 119, 299-326 (1890)
10. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 132, 1488-1501 (1960)
11. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243(5405), 290-293 (1973)
12. Shih C, Weinberg RA. Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 29(1), 161-169 (1982)
13. Goldfarb M, Shimizu K, Perucho M et al. Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature 296(5856), 404-409 (1982) (Pubitemid 12108522)
14. Pulciani S, Santos E, Lauver AV et al. Oncogenes in human tumor cell lines: molecular cloning of a transforming gene from human bladder carcinoma cells. Proc. Natl Acad. Sci. USA 79(9), 2845-2849 (1982) (Pubitemid 12032329)
15. Parada LF, Tabin CJ, Shih C et al. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297(5866), 474-478 (1982) (Pubitemid 12007526)
16. Santos E, Tronick SR, Aaronson SA et al. T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature 298(5872), 343-347 (1982) (Pubitemid 12044286)
17. Der CJ, Krontiris TG, Cooper GM. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc. Natl Acad. Sci. USA 79(11), 3637-3640 (1982) (Pubitemid 12014525)
18. Reddy EP, Reynolds RK, Santos E et al. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300(5888), 149-152 (1982) (Pubitemid 12006347)
19. Tabin CJ, Bradley SM, Bargmann CI et al. Mechanism of activation of a human oncogene. Nature 300(5888), 143-149 (1982) (Pubitemid 12006346)
20. Cavenee WK, Dryja TP, Phillips RA et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305(5937), 779-784 (1983) (Pubitemid 13010953)
21. Friend SH, Bernards R, Rogelj S et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323(6089), 643-646 (1986) (Pubitemid 16008560)
22. Lee WH, Bookstein R, Hong F et al. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235(4794), 1394-1399 (1987) (Pubitemid 17041661)
23. Fung YK, Murphree AL, T?Ang A et al. Structural evidence for the authenticity of the human retinoblastoma gene. Science 236(4809), 1657-1661 (1987) (Pubitemid 17091019)
24. Kallioniemi A, Kallioniemi OP, Sudar D et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258(5083), 818-821 (1992)
25. Pollack JR, Perou CM, Alizadeh AA et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat. Genet. 23(1), 41-46 (1999) (Pubitemid 29418785)
26. Samuelson E, Levan K, Adamovic T et al. Recurrent gene amplifications in human type I endometrial adenocarcinoma detected by fluorescence in situ hybridization. Cancer Genet. Cytogenet. 181(1), 25-30 (2008) (Pubitemid 351192040)
27. Rowley JD. Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann. Genet. 16(2), 109-112 (1973
28. Zech L, Haglund U, Nilsson K et al. Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int. J. Cancer 17(1), 47-56 (1976)
29. Le Beau MM, Larson RA, Bitter MA et al. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. N. Engl. J. Med. 309(11), 630-636 (1983) (Pubitemid 13007568)
30. Larson RA, Kondo K, Vardiman JW et al. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am. J. Med. 76(5), 827-841 (1984) (Pubitemid 14142683)
31. Taub R, Kirsch I, Morton C et al. Translocation of the c-Myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc. Natl Acad. Sci. USA 79(24), 7837-7841 (1982) (Pubitemid 13182474)
32. Tsujimoto Y, Finger LR, Yunis J et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226(4678), 1097-1099 (1984) (Pubitemid 15217831)
33. Abate-Shen C, Shen MM. Diagnostics: the prostate-cancer metabolome. Nature 457(7231), 799-800 (2009)
34. Bickers B, Aukim-Hastie C. New molecular biomarkers for the prognosis and management of prostate cancer - the post PSA era. Anticancer Res. 29(8), 3289-3298 (2009)
35. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748), 644-648 (2005) (Pubitemid 41528150)
36. Mani RS, Tomlins SA, Callahan K et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 326(5957), 1230 (2009)
37. Bradford TJ, Tomlins SA, Wang X et al. Molecular markers of prostate cancer. Urol. Oncol. 24(6), 538-551 (2006) (Pubitemid 44810016)
38. Ashton KJ, Weinstein SR, Maguire DJ et al. Molecular cytogenetic analysis of basal cell carcinoma DNA using comparative genomic hybridization. J. Invest. Dermatol. 117(3), 683-686 (2001) (Pubitemid 32955598)
39. Kobayashi M, Ishida H, Shindo T et al. Molecular analysis of multifocal prostate cancer by comparative genomic hybridization. Prostate 68(16), 1715-1724 (2008)
40. Gao Y, Niu Y, Wang X et al. Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization. J. Mol. Med. 87(2), 145-152 (2009)
41. Chang YC, Yeh KT, Liu TC et al. Molecular cytogenetic characterization of esophageal cancer detected by comparative genomic hybridization. J. Clin. Lab. Anal. 24(3), 167-174 (2010)
42. Solinas-Toldo S, Lampel S, Stilgenbauer S et al. Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 20(4), 399-407 (1997) (Pubitemid 27520090)
43. Pinkel D, Segraves R, Sudar D et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat. Genet. 20(2), 207-211 (1998) (Pubitemid 28455458)
44. Gunn S, Yeh IT, Lytvak I et al. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity. BMC Cancer 10, 396 (2010)
45. Higgins RA, Gunn SR, Robetorye RS. Clinical application of array-based comparative genomic hybridization for the identification of prognostically important genetic alterations in chronic lymphocytic leukemia. Mol. Diagn. Ther. 12(5), 271-280 (2008)
46. Mao X, Young BD, Lu YJ. The application of single nucleotide polymorphism microarrays in cancer research. Curr. Genomics 8(4), 219-228 (2007) (Pubitemid 47232962)
47. Chen Y, Takita J, Choi YL et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455(7215), 971-974 (2008)
48. Janoueix-Lerosey I, Lequin D, Brugieres L et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455(7215), 967-970 (2008)
49. Kidd JM, Cooper GM, Donahue WF et al. Mapping and sequencing of structural variation from eight human genomes. Nature 453(7191), 56-64 (2008) (Pubitemid 351630326)
50. Sudmant PH, Kitzman JO, Antonacci F et al. Diversity of human copy number variation and multicopy genes. Science 330(6004), 641-646 (2010)
51. International HapMap Consortium. The International HapMap Project. Nature 426(6968), 789-796 (2003)
52. Etienne MC, Lagrange JL, Dassonville O et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol. 12(11), 2248-2253 (1994) (Pubitemid 24346691)
53. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 53(22), 5433-5438 (1993) (Pubitemid 23342163)
54. Haiman CA, Stram DO. Exploring genetic susceptibility to cancer in diverse populations. Curr. Opin. Genet. Dev. 20(3), 330-335 (2010)
55. Takata R, Akamatsu S, Kubo M et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat. Genet. 42(9), 751-754 (2010)
56. Kruglyak L. The road to genome-wide association studies. Nat. Rev. Genet. 9(4), 314-318 (2008) (Pubitemid 351399831)
57. Kan YW, Dozy AM. Polymorphism of DNA sequence adjacent to human b-globin structural gene: relationship to sickle mutation. Proc. Natl Acad. Sci. USA 75(11), 5631-5635 (1978) (Pubitemid 9101447)
58. Zenklusen JC, Bieche I, Lidereau R et al. (C-A)n microsatellite repeat D7S522 is the most commonly deleted region in human primary breast cancer. Proc. Natl Acad. Sci. USA 91(25), 12155-12158 (1994)
59. Kennedy GC, Matsuzaki H, Dong S et al. Large-scale genotyping of complex DNA. Nat. Biotechnol. 21(10), 1233-1237 (2003) (Pubitemid 37186182)
60. Matsuzaki H, Loi H, Dong S et al. Parallel genotyping of over 10,000 SNPs using a one-primer assay on a high-density oligonucleotide array. Genome Res. 14(3), 414-425 (2004) (Pubitemid 38380397)
61. Matsuzaki H, Dong S, Loi H et al. Genotyping over 100,000 SNPs on a pair of oligonucleotide arrays. Nat. Methods 1(2), 109-111 (2004)
62. International HapMap Consortium; Frazer KA, Ballinger DG, Cox DR et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 449(7164), 851-861 (2007) (Pubitemid 47598626)
63. 1000 Genomes Project Consortium; Durbin RM, Abecasis GR, Altshuler DL et al. A map of human genome variation from population-scale sequencing. Nature 467(7319), 1061-1073 (2010)
64. Manolio TA. Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363(2), 166-176 (2010)
65. Yoshida T, Ono H, Kuchiba A et al. Genomewide germline analyses on cancer susceptibility and GeMDBJ database: gastric cancer as an example. Cancer Sci. 101(7), 1582-1589 (2010)
66. Slattery ML, Herrick J, Curtin K et al. Increased risk of colon cancer associated with a genetic polymorphism of SMAD7. Cancer Res. 70(4), 1479-1485 (2010)
67. Houlston RS, Cheadle J, Dobbins SE et al. Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat. Genet. 42(11), 973-977 (2010
68. Rothman N, Garcia-Closas M, Chatterjee N et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat. Genet. 42(11), 978-984 (2010)
69. Bolton KL, Tyrer J, Song H et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat. Genet. 42(10), 880-884 (2010)
70. Goode EL, Chenevix-Trench G, Song H et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat. Genet. 42(10), 874-879 (2010)
71. Petersen GM, Amundadottir L, Fuchs CS et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat. Genet. 42(3), 224-228 (2010)
72. Wagner MJ. Pharmacogenetics and personal genomes. Per. Med. 6(6), 643-652 (2009)
73. Gibson G, Goldstein DB. Human genetics: the hidden text of genome-wide associations. Curr. Biol. 17(21), R929-R932 (2007) (Pubitemid 350016909)
74. Hall JM, Lee MK, Newman B et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250(4988), 1684-1689 (1990) (Pubitemid 120031871)
75. Wooster R, Neuhausen SL, Mangion J et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265(5181), 2088-2090 (1994) (Pubitemid 24325690)
76. Bodmer WF, Bailey CJ, Bodmer J et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 328(6131), 614-616 (1987) (Pubitemid 17103960)
77. Lindblom A, Tannergard P, Werelius B et al. Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer. Nat. Genet. 5(3), 279-282 (1993) (Pubitemid 23330393)
78. Peltomaki P, Aaltonen LA, Sistonen P et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science 260(5109), 810-812 (1993) (Pubitemid 23167610)
79. Cannon-Albright LA, Goldgar DE, Meyer LJ et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 258(5085), 1148-1152 (1992)
80. Rapley EA, Crockford GP, Teare D et al. Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat. Genet. 24(2), 197-200 (2000) (Pubitemid 30094725)
81. de Jong MM, Nolte IM, te Meerman GJ et al. Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 11(11), 1332-1352 (2002) (Pubitemid 35340368)
82. Houlston RS, Peto J. The search for low-penetrance cancer susceptibility alleles. Oncogene 23(38), 6471-6476 (2004) (Pubitemid 39265510)
83. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. 1977. Biotechnology 24, 104-108 (1992
84. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417(6892), 949-954 (2002) (Pubitemid 34716871)
85. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670), 554 (2004) (Pubitemid 38541907)
86. Carpten JD, Faber AL, Horn C et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448(7152), 439-444 (2007) (Pubitemid 47123510)
87. Stephens P, Hunter C, Bignell G et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431(7008), 525-526 (2004)
88. Bardelli A, Parsons DW, Silliman N et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300(5621), 949 (2003) (Pubitemid 36548874)
89. Greenman C, Stephens P, Smith R et al. Patterns of somatic mutation in human cancer genomes. Nature 446(7132), 153-158 (2007) (Pubitemid 46398669)
90. Erkko H, Xia B, Nikkila J et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature 446(7133), 316-319 (2007) (Pubitemid 46426155)
91. Guilford P, Hopkins J, Harraway J et al. E-cadherin germline mutations in familial gastric cancer. Nature 392(6674), 402-405 (1998)
92. Meindl A, Hellebrand H, Wiek C et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat. Genet. 42(5), 410-414 (2010)
93. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216), 1061-1068 (2008)
94. Margulies M, Egholm M, Altman WE et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 437(7057), 376-380 (2005) (Pubitemid 41613494)
95. Bennett S. Solexa Ltd. Pharmacogenomics 5(4), 433-438 (2004)
96. Bennett ST, Barnes C, Cox A et al. Toward the 1,000 dollars human genome. Pharmacogenomics 6(4), 373-382 (2005) (Pubitemid 40916360)
97. Bentley DR. Whole-genome re-sequencing. Curr. Opin. Genet. Dev. 16(6), 545-552 (2006) (Pubitemid 44738530)
98. McKernan KJ, Peckham HE, Costa GL et al. Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding. Genome Res. 19(9), 1527-1541 (2009)
99. Thompson JF, Steinmann KE. Single molecule sequencing with a HeliScope genetic analysis system. Curr. Protoc. Mol. Biol. Chapter 7, Unit 7.10 (2010)
100. Holt RA, Jones SJ. The new paradigm of flow cell sequencing. Genome Res. 18(6), 839-846 (2008) (Pubitemid 351793056)
101. Check Hayden E. Human genome at ten: life is complicated. Nature 464(7289), 664-667 (2010)
102. Clarke J, Wu HC, Jayasinghe L et al. Continuous base identification for single-molecule nanopore DNA sequencing. Nat. Nanotechnol 4(4), 265-270 (2009)
103. Uemura S, Aitken CE, Korlach J et al. Real-time tRNA transit on single translating ribosomes at codon resolution. Nature 464(7291), 1012-1017 (2010)
104. The human genome at ten. Nature 464(7289), 649-650 (2010)
105. Collins FS, Barker AD. Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci. Am. 296(3), 50-57 (2007)
106. Verhaak RG, Goudswaard CS, van Putten W et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106(12), 3747-3754 (2005) (Pubitemid 41739008)
107. Ley TJ, Mardis ER, Ding L et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456(7218), 66-72 (2008)
108. Jones S, Hruban RH, Kamiyama M et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324(5924), 217 (2009)
109. Blackford A, Serrano OK, Wolfgang CL et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin. Cancer Res. 15(14), 4674-4679 (2009)
110. Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360(8), 765-773 (2009)
111. Yen KE, Bittinger MA, Su SM et al. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 29(49), 6409-6417 (2010
112. Sanson M, Marie Y, Paris S et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol. 27(25), 4150-4154 (2009)
113. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005) (Pubitemid 40349502)
114. Pleasance ED, Cheetham RK, Stephens PJ et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463(7278), 191-196 (2010)
115. Pleasance ED, Stephens PJ, O?Meara S et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463(7278), 184-190 (2010)
116. Lee W, Jiang Z, Liu J et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465(7297), 473-477 (2010)
117. Ding L, Ellis MJ, Li S et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291), 999-1005 (2010)
118. Shah SP, Morin RD, Khattra J et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461(7265), 809-813 (2009)
119. Yachida S, Jones S, Bozic I et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319), 1114-1117 (2010)
120. Campbell PJ, Yachida S, Mudie LJ et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467(7319), 1109-1113 (2010)
121. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat. Rev. Cancer 6(6), 449-458 (2006)
122. Jones SJ, Laskin J, Li YY et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol. 11(8), R82 (2010)
123. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301(5895), 89-92 (1983) (Pubitemid 13154475)
124. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358(11), 1148-1159 (2008)
125. Greger V, Passarge E, Hopping W et al. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum. Genet. 83(2), 155-158 (1989) (Pubitemid 19234564)
126. Sakai T, Toguchida J, Ohtani N et al. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am. J. Hum. Genet. 48(5), 880-888 (1991) (Pubitemid 21891632)
127. Ohtani-Fujita N, Fujita T, Aoike A et al. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene 8(4), 1063-1067 (1993) (Pubitemid 23087441)
128. Herman JG, Latif F, Weng Y et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91(21), 9700-9704 (1994) (Pubitemid 24311875)
129. Merlo A, Herman JG, Mao L et al. 5? CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1(7), 686-692 (1995)
130. Herman JG, Merlo A, Mao L et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55(20), 4525-4530 (1995)
131. Gonzalez-Zulueta M, Bender CM, Yang AS et al. Methylation of the 5? CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55(20), 4531-4535 (1995)
132. Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 5(19), 2220-2222 (2006) (Pubitemid 44546557)
133. Lujambio A, Ropero S, Ballestar E et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 67(4), 1424-1429 (2007) (Pubitemid 46383366)
134. Jones S, Wang TL, Shih I et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330(6001), 228-231 (2010)
135. Varela I, Tarpey P, Raine K et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469(7331), 539-542 (2011)
136. Medina PP, Romero OA, Kohno T et al. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum. Mutat. 29(5), 617-622 (2008) (Pubitemid 351614585)
137. Dalgliesh GL, Furge K, Greenman C et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463(7279), 360-363 (2010)
138. van Haaften G, Dalgliesh GL, Davies H et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41(5), 521-523 (2009
139. Morin RD, Johnson NA, Severson TM et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42(2), 181-185 (2010)
140. Chan TL, Yuen ST, Kong CK et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat. Genet. 38(10), 1178-1183 (2006) (Pubitemid 44470364)
141. Hitchins MP, Wong JJ, Suthers G et al. Inheritance of a cancer-associated MLH1 germ-line epimutation. N. Engl. J. Med. 356(7), 697-705 (2007)
142. Ley TJ, Ding L, Walter MJ et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363(25), 2424-2433 (2010)
143. Baylin SB, Esteller M, Rountree MR et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 10(7), 687-692 (2001) (Pubitemid 32331576)
144. Hoshino I, Matsubara H. Recent advances in histone deacetylase targeted cancer therapy. Surg. Today 40(9), 809-815 (2010)
145. Costello JF, Fruhwald MC, Smiraglia DJ et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 24(2), 132-138 (2000) (Pubitemid 30094712)
146. van Steensel B, Henikoff S. Epigenomic profiling using microarrays. Biotechniques 35(2), 346-350, 352-354, 356-357 (2003)
147. Meissner A, Gnirke A, Bell GW et al. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res. 33(18), 5868-5877 (2005) (Pubitemid 41742606)
148. Hu M, Yao J, Polyak K. Methylation-specific digital karyotyping. Nat. Protoc. 1(3), 1621-1636 (2006)
149. Lee TI, Johnstone SE, Young RA. Chromatin immunoprecipitation and microarray-based analysis of protein location. Nat. Protoc. 1(2), 729-748 (2006)
150. Robertson G, Hirst M, Bainbridge M et al. Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat. Methods 4(8), 651-657 (2007) (Pubitemid 47202477)
151. Jacinto FV, Ballestar E, Esteller M. Methyl-DNA immunoprecipitation (MeDIP): hunting down the DNA methylome. Biotechniques 44(1), 35, 37, 39 passim (2008)
152. Harris RA, Wang T, Coarfa C et al. Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat. Biotechnol. 28(10), 1097-1105 (2010
153. Chiang PW, Song WJ, Wu KY et al. Use of a fluorescent-PCR reaction to detect genomic sequence copy number and transcriptional abundance. Genome Res. 6(10), 1013-1026 (1996)
154. Heid CA, Stevens J, Livak KJ et al. Real time quantitative PCR. Genome Res. 6(10), 986-994 (1996) (Pubitemid 26388091)
155. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res. 6(10), 995-1001 (1996) (Pubitemid 26388092)
156. Lallemant B, Evrard A, Combescure C et al. Clinical relevance of nine transcriptional molecular markers for the diagnosis of head and neck squamous cell carcinoma in tissue and saliva rinse. BMC Cancer 9, 370 (2009)
157. Lossos IS, Czerwinski DK, Alizadeh AA et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N. Engl. J. Med. 350(18), 1828-1837 (2004) (Pubitemid 38917249)
158. Raynal C, Pascussi JM, Leguelinel G et al. Pregnane X receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol. Cancer 9, 46 (2010)
159. Schena M, Shalon D, Davis RW et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270(5235), 467-470 (1995)
160. Schena M. Genome analysis with gene expression microarrays. Bioessays 18(5), 427-431 (1996) (Pubitemid 126599968)
161. Khan J, Simon R, Bittner M et al. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res. 58(22), 5009-5013 (1998) (Pubitemid 28521149)
162. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286(5439), 531-537 (1999)
163. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769), 503-511 (2000) (Pubitemid 30082188)
164. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747-752 (2000)
165. Bittner M, Meltzer P, Chen Y et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406(6795), 536-540 (2000) (Pubitemid 30625740)
166. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001) (Pubitemid 32878711)
167. Garber ME, Troyanskaya OG, Schluens K et al. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl Acad. Sci. USA 98(24), 13784-13789 (2001) (Pubitemid 33115976)
168. Bhattacharjee A, Richards WG, Staunton J et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA 98(24), 13790-13795 (2001) (Pubitemid 33115977)
169. Dhanasekaran SM, Barrette TR, Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412(6849), 822-826 (2001) (Pubitemid 32801464)
170. Lapointe J, Li C, Higgins JP et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA 101(3), 811-816 (2004) (Pubitemid 38121040)
171. Bullinger L, Dohner K, Bair E et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350(16), 1605-1616 (2004) (Pubitemid 38501163)
172. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871), 530-536 (2002)
173. Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460), 671-679 (2005) (Pubitemid 40260888)
174. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(25), 1937-1947 (2002) (Pubitemid 34651353)
175. van de Vijver MJ, He YD, van?t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002) (Pubitemid 35461656)
176. Glinsky GV, Higashiyama T, Glinskii AB. Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm. Clin. Cancer Res. 10(7), 2272-2283 (2004) (Pubitemid 38445684)
177. Potti A, Mukherjee S, Petersen R et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N. Engl. J. Med. 355(6), 570-580 (2006) (Pubitemid 44200650)
178. Kudoh K, Ramanna M, Ravatn R et al. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 60(15), 4161-4166 (2000) (Pubitemid 30636599)
179. Scherf U, Ross DT, Waltham M et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24(3), 236-244 (2000) (Pubitemid 30132190)
180. Wang W, Marsh S, Cassidy J et al. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res. 61(14), 5505-5510 (2001) (Pubitemid 32694934)
181. Kihara C, Tsunoda T, Tanaka T et al. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res. 61(17), 6474-6479 (2001) (Pubitemid 32783254)
182. Zembutsu H, Ohnishi Y, Tsunoda T et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 62(2), 518-527 (2002) (Pubitemid 34106426)
183. Hofmann WK, de Vos S, Elashoff D et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 359(9305), 481-486 (2002) (Pubitemid 34164295)
184. Higuchi E, Oridate N, Furuta Y et al. Differentially expressed genes associated with CIS-diamminedichloroplatinum (II) resistance in head and neck cancer using differential display and cDNA microarray. Head Neck 25(3), 187-193 (2003) (Pubitemid 36245876)
185. Tan PK, Downey TJ, Spitznagel EL Jr et al. Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res. 31(19), 5676-5684 (2003) (Pubitemid 37441938)
186. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat. Rev. Cancer 5(2), 142-149 (2005) (Pubitemid 40215862)
187. Leek JT, Scharpf RB, Bravo HC et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat. Rev. Genet. 11(10), 733-739 (2010)
188. Baggerly KA, Coombes KR, Neeley ES. Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer. J. Clin. Oncol. 26(7), 1186-1187; author reply 1187-1188 (2008)
189. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 6(4), 259-269 (2006)
190. De Smaele E, Ferretti E, Gulino A. MicroRNAs as biomarkers for CNS cancer and other disorders. Brain Res. 1338, 100-111 (2010)
191. Sioud M, Cekaite L. Profiling of miRNA expression and prediction of target genes. Methods Mol. Biol. 629, 257-271 (2010
192. Chiang PW, Song WJ, Wu KY et al. Use of a fluorescent-PCR reaction to detect genomic sequence copy number and transcriptional abundance. Genome Res. 6(10), 1013-1026 (1996)
193. Heid CA, Stevens J, Livak KJ et al. Real time quantitative PCR. Genome Res. 6(10), 986-994 (1996) (Pubitemid 26388091)
194. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res. 6(10), 995-1001 (1996) (Pubitemid 26388092)
195. Lallemant B, Evrard A, Combescure C et al. Clinical relevance of nine transcriptional molecular markers for the diagnosis of head and neck squamous cell carcinoma in tissue and saliva rinse. BMC Cancer 9, 370 (2009)
196. Lossos IS, Czerwinski DK, Alizadeh AA et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N. Engl. J. Med. 350(18), 1828-1837 (2004) (Pubitemid 38917249)
197. Raynal C, Pascussi JM, Leguelinel G et al. Pregnane X receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol. Cancer 9, 46 (2010)
198. Schena M, Shalon D, Davis RW et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270(5235), 467-470 (1995)
199. Schena M. Genome analysis with gene expression microarrays. Bioessays 18(5), 427-431 (1996) (Pubitemid 126599968)
200. Khan J, Simon R, Bittner M et al. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res. 58(22), 5009-5013 (1998) (Pubitemid 28521149)
201. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286(5439), 531-537 (1999)
202. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769), 503-511 (2000) (Pubitemid 30082188)
203. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747-752 (2000)
204. Bittner M, Meltzer P, Chen Y et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406(6795), 536-540 (2000) (Pubitemid 30625740)
205. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001) (Pubitemid 32878711)
206. Garber ME, Troyanskaya OG, Schluens K et al. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl Acad. Sci. USA 98(24), 13784-13789 (2001) (Pubitemid 33115976)
207. Bhattacharjee A, Richards WG, Staunton J et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA 98(24), 13790-13795 (2001) (Pubitemid 33115977)
208. Dhanasekaran SM, Barrette TR, Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412(6849), 822-826 (2001) (Pubitemid 32801464)
209. Lapointe J, Li C, Higgins JP et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA 101(3), 811-816 (2004) (Pubitemid 38121040)
210. Bullinger L, Dohner K, Bair E et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350(16), 1605-1616 (2004) (Pubitemid 38501163)
211. van ?t Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871), 530-536 (2002)
212. Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460), 671-679 (2005) (Pubitemid 40260888)
213. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(25), 1937-1947 (2002) (Pubitemid 34651353)
214. van de Vijver MJ, He YD, van?t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002) (Pubitemid 35461656)
215. Glinsky GV, Higashiyama T, Glinskii AB. Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm. Clin. Cancer Res. 10(7), 2272-2283 (2004) (Pubitemid 38445684)
216. Potti A, Mukherjee S, Petersen R et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N. Engl. J. Med. 355(6), 570-580 (2006) (Pubitemid 44200650)
217. Kudoh K, Ramanna M, Ravatn R et al. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 60(15), 4161-4166 (2000) (Pubitemid 30636599)
218. Scherf U, Ross DT, Waltham M et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24(3), 236-244 (2000) (Pubitemid 30132190)
219. Wang W, Marsh S, Cassidy J et al. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res. 61(14), 5505-5510 (2001) (Pubitemid 32694934)
220. Kihara C, Tsunoda T, Tanaka T et al. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res. 61(17), 6474-6479 (2001) (Pubitemid 32783254)
221. Zembutsu H, Ohnishi Y, Tsunoda T et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 62(2), 518-527 (2002) (Pubitemid 34106426)
222. Hofmann WK, de Vos S, Elashoff D et al. Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 359(9305), 481-486 (2002) (Pubitemid 34164295)
223. Higuchi E, Oridate N, Furuta Y et al. Differentially expressed genes associated with CIS-diamminedichloroplatinum (II) resistance in head and neck cancer using differential display and cDNA microarray. Head Neck 25(3), 187-193 (2003) (Pubitemid 36245876)
224. Tan PK, Downey TJ, Spitznagel EL Jr et al. Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res. 31(19), 5676-5684 (2003) (Pubitemid 37441938)
225. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat. Rev. Cancer 5(2), 142-149 (2005) (Pubitemid 40215862)
226. Leek JT, Scharpf RB, Bravo HC et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat. Rev. Genet. 11(10), 733-739 (2010)
227. Baggerly KA, Coombes KR, Neeley ES. Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer. J. Clin. Oncol. 26(7), 1186-1187; author reply 1187-1188 (2008)
228. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 6(4), 259-269 (2006)
229. De Smaele E, Ferretti E, Gulino A. MicroRNAs as biomarkers for CNS cancer and other disorders. Brain Res. 1338, 100-111 (2010)
230. Sioud M, Cekaite L. Profiling of miRNA expression and prediction of target genes. Methods Mol. Biol. 629, 257-271 (2010
231. Sjoholt G, Bedringaas SL, Doskeland AP et al. Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML). Curr. Pharm. Biotechnol. 7(3), 159-170 (2006) (Pubitemid 43881080)
232. Fine JM, Creyssel R. Starch gel electrophoresis studies on abnormal proteins in myeloma and macroglobulinaemia. Nature 183(4658), 392 (1959)
233. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17(1), 43-52 (1979 (Pubitemid 9188209)
234. Liang P, Pardee AB. Analysing differential gene expression in cancer. Nat. Rev. Cancer 3(11), 869-876 (2003) (Pubitemid 37376983)
235. Hanash SM, Baier LJ, McCurry L et al. Lineage-related polypeptide markers in acute lymphoblastic leukemia detected by two-dimensional gel electrophoresis. Proc. Natl Acad. Sci. USA 83(3), 807-811 (1986) (Pubitemid 16035564)
236. Haab BB. Advances in protein microarray technology for protein expression and interaction profiling. Curr. Opin. Drug Discov. Devel. 4(1), 116-123 (2001) (Pubitemid 32118467)
237. Sreekumar A, Nyati MK, Varambally S et al. Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res. 61(20), 7585-7593 (2001) (Pubitemid 32995052)
238. Paweletz CP, Charboneau L, Bichsel VE et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20(16), 1981-1989 (2001) (Pubitemid 32458030)
239. Nielsen UB, Cardone MH, Sinskey AJ et al. Profiling receptor tyrosine kinase activation by using Ab microarrays. Proc. Natl Acad. Sci. USA 100(16), 9330-9335 (2003) (Pubitemid 37033928)
240. Zha H, Raffeld M, Charboneau L et al. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab. Invest. 84(2), 235-244 (2004) (Pubitemid 41656505)
241. VanMeter A, Signore M, Pierobon M et al. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev. Mol. Diagn. 7(5), 625-633 (2007) (Pubitemid 47547727)
242. Espina V, Wulfkuhle JD, Calvert VS et al. Reverse phase protein microarrays for monitoring biological responses. Methods Mol. Biol. 383, 321-336 (2007)
243. Shi W, Meng Z, Chen Z et al. Proteome analysis of human pancreatic cancer cell lines with highly liver metastatic potential by antibody microarray. Mol. Cell. Biochem. (2010)
244. Zheng Y, Xu Y, Ye B et al. Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 98(12), 2576-2582 (2003) (Pubitemid 37509520)
245. Cheung PK, Woolcock B, Adomat H et al. Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res. 64(17), 5929-5933 (2004) (Pubitemid 39129386)
246. Lu M, Whelan SA, He J et al. Hydrophobic proteome analysis of triple negative and hormone-receptor-positive-Her2-negative breast cancer by mass spectrometer. Clin. Proteomics 6(3), 93-103 (2010)
247. Pawa N, Wright JM, Arulampalam TH. Mass spectrometry based proteomic profiling for pancreatic cancer. JOP 11(5), 423-426 (2010)
248. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 422(6928), 198-207 (2003) (Pubitemid 36362757)
249. Yanagisawa K, Tomida S, Shimada Y et al. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J. Natl Cancer Inst. 99(11), 858-867 (2007)
250. Handschuh G, Candidus S, Luber B et al. Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene 18(30), 4301-4312 (1999) (Pubitemid 29392371)
251. Mitchell P. A perspective on protein microarrays. Nat. Biotechnol. 20(3), 225-229 (2002) (Pubitemid 34205415)
252. Zhu H, Snyder M. Protein chip technology. Curr. Opin. Chem. Biol. 7(1), 55-63 (2003) (Pubitemid 36126493)
253. Sun Z, Fu X, Zhang L et al. A protein chip system for parallel analysis of multi-tumor markers and its application in cancer detection. Anticancer Res. 24(2C), 1159-1165 (2004) (Pubitemid 38624956)
254. Albitar M, Potts SJ, Giles FJ et al. Proteomics-based prediction of clinical response in acute myeloid leukemia. Exp. Hematol. 37(7), 784-790 (2009)
255. Moscova M, Marsh DJ, Baxter RC. Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines. Cancer Res. 66(3), 1376-1383 (2006) (Pubitemid 43259917)
256. Heo SH, Lee SJ, Ryoo HM et al. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. Proteomics 7(23), 4292-4302 (2007)
257. Kim YS, Hwang SY, Kang HY et al. Functional proteomics study reveals that N-acetylglucosaminyltransferase V reinforces the invasive/metastatic potential of colon cancer through aberrant glycosylation on tissue inhibitor of metalloproteinase-1. Mol. Cell Proteomics 7(1), 1-14 (2008) (Pubitemid 351248231)
258. Hanash S, Taguchi A. The grand challenge to decipher the cancer proteome. Nat. Rev. Cancer 10(9), 652-660 (2010)
259. Vercoutter-Edouart AS, Slomianny MC, Dekeyzer-Beseme O et al. Glycoproteomics and glycomics investigation of membrane N-glycosylproteins from human colon carcinoma cells. Proteomics 8(16), 3236-3256 (2008)
260. Taylor AD, Hancock WS, Hincapie M et al. Towards an integrated proteomic and glycomic approach to finding cancer biomarkers. Genome Med. 1(6), 57 (2009)
261. Blokzijl A, Friedman M, Ponten F et al. Profiling protein expression and interactions: proximity ligation as a tool for personalized medicine. J. Intern. Med. 268(3), 232-245 (2010)
262. Wilkinson GR. Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352(21), 2211-2221 (2005)
263. Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol. 15(4), 273-280 (1996) (Pubitemid 26124084)
264. Motulsky AG. Drug reactions enzymes, and biochemical genetics. JAMA 165(7), 835-837 (1957)
265. Vogel F. Moderne problem der humangenetik. Ergeb. Inn. Med. U. Kinderheilk. 12, 52-125 (1959)
266. Vesell ES, Page JG. Genetic control of drug levels in man: phenylbutazone. Science 159(3822), 1479-1480 (1968)
267. Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. BMJ 2(5197), 485-491 (1960)
268. Evans DA. N-acetyltransferase. Pharmacol. Ther. 42(2), 157-234 (1989) (Pubitemid 19140452)
269. Grant DM, Morike K, Eichelbaum M et al. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J. Clin. Invest. 85(3), 968-972 (1990) (Pubitemid 20087504)
270. Hammer W, Sjoqvist F. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci. 6(17), 1895-1903 (1967)
271. Mahgoub A, Idle JR, Dring LG et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 2(8038), 584-586 (1977 (Pubitemid 8176607)
272. Eichelbaum M, Spannbrucker N, Dengler HJ. Influence of the defective metabolism of sparteine on its pharmacokinetics. Eur. J. Clin. Pharmacol. 16(3), 189-194 (1979) (Pubitemid 10227379)
273. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5(1), 6-13 (2005) (Pubitemid 40220611)
274. Gonzalez FJ, Skoda RC, Kimura S et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331(6155), 442-446 (1988 (Pubitemid 18064368)
275. Skoda RC, Gonzalez FJ, Demierre A et al. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc. Natl Acad. Sci. USA 85(14), 5240-5243 (1988)
276. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336(8714), 529-532 (1990) (Pubitemid 20278099)
277. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat. Rev. Cancer 1(2), 99-108 (2001) (Pubitemid 33741885)
278. Kafka A, Sauer G, Jaeger C et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int. J. Oncol. 22(5), 1117-1121 (2003)
279. Lepper ER, Nooter K, Verweij J et al. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 6(2), 115-138 (2005) (Pubitemid 40613179)
280. Etienne MC, Formento JL, Chazal M et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 14(12), 785-792 (2004) (Pubitemid 40054334)
281. Beverage JN, Sissung TM, Sion AM et al. CYP2D6 polymorphisms and the impact on tamoxifen therapy. J. Pharm. Sci. 96(9), 2224-2231 (2007) (Pubitemid 47477881)
282. Stanulla M, Schaeffeler E, Flohr T et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 293(12), 1485-1489 (2005) (Pubitemid 40393293)
283. Khan O, Fotheringham S, Wood V et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc. Natl Acad. Sci. USA 107(14), 6532-6537 (2010)
284. Agrelo R, Cheng WH, Setien F et al. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc. Natl Acad. Sci. USA 103(23), 8822-8827 (2006) (Pubitemid 43878103)
285. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 112(13), 4808-4817 (2008)
286. Druker BJ, Guilhot F, O?Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355(23), 2408-2417 (2006) (Pubitemid 44903745)
287. Hughes TP, Kaeda J, Branford S et al. Frequency of major molecular responses to imatinib or interferon a plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349(15), 1423-1432 (2003) (Pubitemid 37211057)
288. O?Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348(11), 994-1004 (2003) (Pubitemid 36302244)
289. Saglio G, Kim DW, Issaragrisil S et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362(24), 2251-2259 (2010)
290. Weisberg E, Manley PW, Breitenstein W et al. Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL. Cancer Cell 7(2), 129-141 (2005) (Pubitemid 40248339)
291. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5(6), 649-655 (1982) (Pubitemid 13149996)
292. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in ?good-risk? chronic granulocytic leukemia. Blood 63(4), 789-799 (1984) (Pubitemid 14141296)
293. Garland P, Apperley J. Nilotinib: evaluation and analysis of its role in chronic myeloid leukemia. Future Oncol. 7(2), 201-218 (2011)
294. Sleijfer S, Wiemer E, Verweij J. Drug insight: gastrointestinal stromal tumors (GIST) - the solid tumor model for cancer-specific treatment. Nat. Clin. Pract. Oncol. 5(2), 102-111 (2008) (Pubitemid 351188931)
295. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177-182 (1987) (Pubitemid 17231334)
296. Liu E, Thor A, He M et al. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 7(5), 1027-1032 (1992)
297. Ciocca DR, Fujimura FK, Tandon AK et al. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J. Natl Cancer Inst. 84(16), 1279-1282 (1992)
298. Mariani G, Fasolo A, De Benedictis E et al. Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat. Clin. Pract. Oncol. 6(2), 93-104 (2009)
299. Verstovsek S, Kantarjian H, Mesa RA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363(12), 1117-1127 (2010)
300. Shilling AD, Nedza FM, Emm T et al. Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab. Dispos. 38(11), 2023-2031 (2010)
301. Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352(17), 1779-1790 (2005) (Pubitemid 40570926)
302. Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4), 387-397 (2005) (Pubitemid 40544655)
303. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361(2), 123-134 (2009)
304. Fong PC, Yap TA, Boss DS et al. Poly(ADP)- ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28(15), 2512-2519 (2010)
305. Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat. Med. 17(3), 297-303 (2011)
306. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363(9), 809-819 (2010)
307. Garber K. Cancer research. Melanoma drug vindicates targeted approach. Science 326(5960), 1619 (2009)
308. Becquemont L, Alfirevic A, Amstutz U et al. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 12(1), 113-124 (2010)
309. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 10(11), 760-774 (2010)
310. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361(10), 958-967 (2009
311. Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359(4), 366-377 (2008)
312. Gridelli C, De Marinis F, Di Maio M et al. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: review of the evidence. Lung Cancer 71(3), 249-257 (2011)
313. Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23(25), 5900-5909 (2005)
314. Lievre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66(8), 3992-3995 (2006)
315. Lievre A, Laurent-Puig P. Genetics: predictive value of KRAS mutations in chemoresistant CRC. Nat. Rev. Clin. Oncol. 6(6), 306-307 (2009)
316. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408-1417 (2009)
317. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757-1765 (2008)
318. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008)
319. Palanisamy N, Ateeq B, Kalyana-Sundaram S et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat. Med. 16(7), 793-798 (2010)
320. Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr. Opin. Hematol. 11(1), 35-43 (2004) (Pubitemid 38021719)
321. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153), 561-566 (2007) (Pubitemid 47206930)
322. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363(18), 1693-1703 (2010)
323. Choi YL, Soda M, Yamashita Y et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363(18), 1734-1739 (2010)
324. Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468(7326), 973-977 (2010)
325. Srinivasan BS, Chen J, Cheng C et al. Methods for analysis in pharmacogenomics: lessons from the pharmacogenetics research network analysis group. Pharmacogenomics 10(2), 243-251 (2009)
326. Lunshof JE, Bobe J, Aach J et al. Personal genomes in progress: from the human genome project to the personal genome project. Dialogues Clin. Neurosci. 12(1), 47-60 (2010)
327. Steele FR. Personalized medicine: something old, something new. Pers. Med. 6(1), 1-5 (2009)
328. Hayden EC. Personalized cancer therapy gets closer. Nature 458(7235), 131-132 (2009)
329. Freidlin B, McShane LM, Korn EL: Randomized clinical trials with biomarkers: design issues. J. Natl Cancer Inst. 102(3), 152-160 (2010)
330. Tursz T, Andre F, Lazar V et al. Implications of personalized medicine - perspective from a cancer center. Nat. Rev. Clin. Oncol. 8(3), 177-183 (2011)
331. Schilsky RL. Personalized medicine in oncology: the future is now. Nat. Rev. Drug Discov. 9(5), 363-366 (2010)
332. Hamburg MA, Sharfstein JM. The FDA as a public health agency. N. Engl. J. Med. 360(24), 2493-2495 (2009)
333. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J. Clin.
334. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl. Res. 154(6), 277-287 (2009)
335. Biesecker LG, Mullikin JC, Facio FM et al. The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. Genome Res. 19(9), 1665-1674 (2009
336. The SNP Consortium